• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Newsletters » The Carlat Psychiatry Report
psychiatry-report-header.png

The Carlat Psychiatry Report

Treating Personality Disorders (September) | 2008

View Archived Issues

Topics in Personality Disorders

September 1, 2008
Are you diagnosing a personality disorder (PD) in half of your patients? If not, you probably are not asking enough questions. Read More

Medications for Borderline Personality Disorder

September 1, 2008
Most authorities in the world of borderline personality disorder (BPD) say that psychotherapy is the mainstay of treatment and that medications should only be used adjunctively to treat symptoms as they arise. Nevertheless, medications are used relatively frequently for this disorder. Read More

Gabitril fails to improve GAD symptoms in three controlled trials

September 1, 2008
Cephalon’s selective GABA reuptake inhibitor, the antiepileptic drug tiagabine (Gabitril), was assessed for the treatment of generalized anxiety disorder in adults in three large 10-week placebo-controlled studies. Read More

Vanda’s antipsychotic candidate iloperidone rejected by FDA

September 1, 2008
The FDA issued a Not Approvable letter regarding Vanda Pharmaceutical’s antipsychotic medication iloperidone (Fanapta). The agency based its decision on iloperidone’s question able efficacy results versus risperidone. Read More

Placebo response is usually long-lasting

September 1, 2008
Based on data from eight randomized double-blind, placebo-controlled trials, researchers found that 79% of patients who responded to placebo in the initial phase of the trial maintained their response while continuing to take placebo during the continuation phase of the trial. Read More

Intensive early intervention benefits fade after treatment discontinued

September 1, 2008
An intensive two-year-long early intervention for first episode psychosis showed early promise relative to standard care, yielding superior improvement in both positive and negative symptoms, as well as lower rates of substance abuse and lower antipsychotic medication doses. Read More

Learning Objectives, Treating Personality Disorders, TCPR, September 2008

September 1, 2008
After reading these articles, you should be able to… Read More
SUBSCRIBE NOW
DOWNLOAD NOW
Editor-in-Chief
Aiken.png
Chris Aiken, MD
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.

Full Editorial Information
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.